-
- ADME/DMPK for Stroke DrugsDrug Efficacy Testing for Stroke
- Cerebral Infarct Size Measurement
- Histological Assessment
- Physiological Monitoring
- Behavioral TestingBrain Imaging
- Cerebral Blood Flow Monitoring
- Brain Edema Measurement
- Assessment of Blood-Brain Barrier
- Assessment of Leukocyte-Platelet Aggregates
- Quantitative Analysis of Protein and mRNA Expression
Safety Assessment for Stroke DrugsIn Vitro Pharmacology for Stroke Drugs- Cell Viability Assay
- Caspase-3 Activity Assay
- In Vitro Neuroinflammatory Models and Assays
- Excitotoxicity In Vitro Assay
- Cell-Based Mitochondrial Function Assay
- In Vitro Oxidative Stress Assay
- Analysis of Ischemia-Triggered Glutamate Excitotoxicity
- NMDA Receptor-mediated Excitotoxicity
- AMPA Receptor-mediated Excitotoxicity
Molecular Mechanism Analysis of Oxidative Stress in StrokeAnalysis of Neuroinflammatory Mechanisms in Stroke- Molecular Mechanism Analysis of Ischemia-Reperfusion Injury
Cell Death Mechanism Analysis in Stroke- Autophagy Mechanism Analysis in StrokeApoptotic Mechanism Analysis after Cerebral Ischemia
- Ferroptosis Pathways
- Necroptosis Signaling Pathways
Epigenetic Mechanism Analysis in Stroke- Analysis of Gut Microbiota in Stroke
- Animal Modeling of Stroke
- Animal Modeling of Ischemic StrokeAnimal Modeling of Hemorrhagic StrokeIn Vitro Modeling of Stroke
- In Vitro Modeling of Ischemic Stroke
- In Vitro Modeling of Hemorrhagic Stroke
- Small-Molecule Antiplatelet DrugsNeuroprotective PeptidesMonoclonal Antibodies for StrokeStem Cell-Based Therapies for StrokeDrug Delivery SystemsInquiry
Small Molecule Drug Development for Stroke
Small molecules are considered to be low molecular weight organic compounds, less than 900 Da (900 g/mol). Many small molecule drugs have been identified, characterized, and critically evaluated in stroke pathology injury due to their membrane permeability and specificity for the protein or process of interest. Based on a growing understanding of the pathophysiological pathways of stroke, small molecules have been developed to interfere with the ischemic cascade, which can attenuate thrombosis, ischemia-induced excitotoxicity, mitochondrial damage and inflammation.
Our Small Molecule Drug Development Services for Stroke
Ace Therapeutics helps clients develop high-quality small molecule drugs for stroke. Our services cover all stages from target identification to preclinical evaluation.
- Target Identification. We provide molecular biology and structural biology technology platforms for target-based small molecule drug discovery for stroke.
- Target Screening and Lead Compound Optimization. We can perform target-based high-throughput screening and obtain composite crystal structures of small molecules for rational optimization with computer assistance.
- Preclinical Evaluation of Small Molecules for stroke. We use cell-based assays and animal models of stroke to evaluate the therapeutic potential of small molecule drugs in terms of neuroprotection, reduction of blood-brain barrier disruption, modulation of inflammatory responses, and improvement of functional outcomes.
Antiplatelet Drug Development for Stroke - Cyclooxygenase inhibitors
- Phosphodiesterase inhibitors
- ADP receptor antagonists
- Membrane protein IIb/IIIa (GP IIb/IIIa) receptor antagonists
- Adenosine receptor antagonists
- 5-hydroxytryptamine (5-HT) receptor antagonists
Why Choose Us
- We have technology platforms for high-throughput screening, virtual screening, and structure- and fragment-based drug design.
- We have reliable and extensive in vitro and animal models of stroke.
- We have an extensive library of compounds for screening.
- We offer mass spectrometry (MS), nuclear magnetic resonance (NMR), gene sequencing, proteomics and other technologies to help you discover new targets.
- We design customized small molecule drug development programs for clients based on specific therapeutic targets.
Ace Therapeutics is committed to helping clients accelerate the development of small molecule drugs for stroke. Our team collaborates with leading academic and pharmaceutical partners to design and execute well-controlled preclinical studies. Please contact us for more information. We look forward to working with you!
Reference- Goenka, L., et al. (2019). Neuroprotective agents in acute ischemic stroke—a reality check. Biomedicine & Pharmacotherapy, 109, 2539-2547.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.Related Services
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket